Table of Contents

company-logo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. The company was founded in 2015 and is headquartered in Shanghai, China.

ImmuneOnco Biopharmaceuticals Dividend Announcement

• ImmuneOnco Biopharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on ImmuneOnco Biopharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

ImmuneOnco Biopharmaceuticals Dividend History

ImmuneOnco Biopharmaceuticals Dividend Yield

ImmuneOnco Biopharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing ImmuneOnco Biopharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

ImmuneOnco Biopharmaceuticals Financial Ratios

P/E ratio-6.11
PEG ratio0.13
P/B ratio5.25
ROE-76.55%
Payout ratio0.00%
Current ratio4.86
Quick ratio4.29
Cash Ratio2.06

ImmuneOnco Biopharmaceuticals Dividend FAQ

Does ImmuneOnco Biopharmaceuticals stock pay dividends?
ImmuneOnco Biopharmaceuticals does not currently pay dividends to its shareholders.
Has ImmuneOnco Biopharmaceuticals ever paid a dividend?
No, ImmuneOnco Biopharmaceuticals has no a history of paying dividends to its shareholders. ImmuneOnco Biopharmaceuticals is not known for its dividend payments.
Why doesn't ImmuneOnco Biopharmaceuticals pay dividends?
There are several potential reasons why ImmuneOnco Biopharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will ImmuneOnco Biopharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While ImmuneOnco Biopharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is ImmuneOnco Biopharmaceuticals a dividend aristocrat?
ImmuneOnco Biopharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is ImmuneOnco Biopharmaceuticals a dividend king?
ImmuneOnco Biopharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is ImmuneOnco Biopharmaceuticals a dividend stock?
No, ImmuneOnco Biopharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy ImmuneOnco Biopharmaceuticals stocks?
To buy ImmuneOnco Biopharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy ImmuneOnco Biopharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.